| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10911414 | Lung Cancer | 2011 | 5 Pages |
Abstract
In advanced NSCLC patients, there were no significant differences between patients with or without KRAS mutations in plasma-free DNA with respect to the baseline characteristics, response rates, PFS or OS.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Carlos Camps, Eloisa Jantus-Lewintre, Andrea Cabrera, Ana Blasco, Elena SanmartÃn, Sandra Gallach, Cristina Caballero, Nieves del Pozo, Rafael Rosell, Ricardo Guijarro, Rafael Sirera,